|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
09886 DINGDANG HEALTH
Nominal 
0.840 +0.030 (+3.704%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 4,887,777 | 4.684% | 4,669,078 | 4,856,806 | 4,329,075 | 3,678,690 |
| Cost of Sales | (3,164,264) | 1.071% | (3,130,729) | (3,346,135) | (2,879,405) | (2,516,379) |
| Gross Profit | 1,723,513 | 12.037% | 1,538,349 | 1,510,671 | 1,449,670 | 1,162,311 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (923) | -99.556% | (207,721) | (356) | (2,506,094) | (912,466) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | (48,304) | (33,337) | |
| Share of Results of Asso. & JCEs | 0 | -- | (1,555) | (2,445) | 0 | 0 | |
| Profit / (Loss) before Taxation | (30,716) | -91.701% | (370,119) | (221,227) | (2,832,147) | (1,581,859) | |
| Taxation | (21,395) | 116.834% | (9,867) | (9,641) | (10,128) | (17,115) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 3,093 | -11.325% | 3,488 | 5,059 | 8,880 | 20,948 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (49,018) | -86.981% | (376,498) | (225,809) | (2,833,395) | (1,578,026) | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (15,479) | -21.957% | (19,834) | (24,749) | (9,233) | 13,611 |
| Depreciation & Amortisation | 140,710 | 1.726% | 138,322 | 139,998 | 135,307 | 135,286 |
| Directors' Emoluments | -- | -- | 98,776 | 119,169 | 157,867 | 311,745 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | -4.000 | -85.714% | -28.000 | -17.000 | -337.000 | -331.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.009) | (0.004) | (0.283) | (0.619) |
| NBV per share ($) | 1.261 | -- | 1.258 | 1.519 | 1.629 | -- |
| Remarks: | Real time quote last updated: 24/03/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -49,018 |
| %Change | -86.981% |
| EPS / (LPS) | RMB -0.040 |
| NBV Per Share (¥) | RMB 1.261 |